Evidence map›Paper›PMID 25870334›Full record

ArticleMolecular pharmacology2015

Desformylflustrabromine (dFBr) and [3H]dFBr-Labeled Binding Sites in a Nicotinic Acetylcholine Receptor.

Ayman K Hamouda, Ze-Jun Wang, Deirdre S Stewart, Atul D Jain, Richard A Glennon, Jonathan B Cohen

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Molecular pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ayman K HamoudaDepartment of Neurobiology, Harvard Medical School, Boston, Massachusetts (A.K.H., D.S.S., J.B.C.); Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia (A.D.J., R.A.G.); and Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M Health Sciences Center, Kingsville,Texas (A.K.H., Z.-J.W.).
Ze-Jun WangDepartment of Neurobiology, Harvard Medical School, Boston, Massachusetts (A.K.H., D.S.S., J.B.C.); Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia (A.D.J., R.A.G.); and Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M Health Sciences Center, Kingsville,Texas (A.K.H., Z.-J.W.).
Deirdre S StewartDepartment of Neurobiology, Harvard Medical School, Boston, Massachusetts (A.K.H., D.S.S., J.B.C.); Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia (A.D.J., R.A.G.); and Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M Health Sciences Center, Kingsville,Texas (A.K.H., Z.-J.W.).
Atul D JainDepartment of Neurobiology, Harvard Medical School, Boston, Massachusetts (A.K.H., D.S.S., J.B.C.); Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia (A.D.J., R.A.G.); and Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M Health Sciences Center, Kingsville,Texas (A.K.H., Z.-J.W.).
Richard A GlennonDepartment of Neurobiology, Harvard Medical School, Boston, Massachusetts (A.K.H., D.S.S., J.B.C.); Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia (A.D.J., R.A.G.); and Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M Health Sciences Center, Kingsville,Texas (A.K.H., Z.-J.W.).
Jonathan B CohenDepartment of Neurobiology, Harvard Medical School, Boston, Massachusetts (A.K.H., D.S.S., J.B.C.); Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia (A.D.J., R.A.G.); and Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M Health Sciences Center, Kingsville,Texas (A.K.H., Z.-J.W.) jonathan_cohen@hms.harvard.edu.
Virginia Commonwealth University · USHarvard University · USVirginia Commonwealth University Medical Center · US

Funding

Synthetic Chemistry CoreP01GM058448 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, KEITH W · 1999 to 2018
$33.6M
Novel, subtype selective potentiators of nicotinic acetycholine receptorsR01NS066059 · NINDS · UNIVERSITY OF ALASKA FAIRBANKS · PI SCHULTE, MARVIN KENNETH · 2009 to 2010
$661k
NIGMS NIH HHS GM-58448NIGMS NIH HHS P01 GM058448NINDS NIH HHS NS-066059NINDS NIH HHS R01 NS066059
6 · The paper itself

Abstract

Desformylflustrabromine (dFBr) is a positive allosteric modulator (PAM) of α4β2 and α2β2 nAChRs that, at concentrations >1 µM, also inhibits these receptors and α7 nAChRs. However, its interactions with muscle-type nAChRs have not been characterized, and the locations of its binding site(s) in any nAChR are not known. We report here that dFBr inhibits human muscle (αβεδ) and Torpedo (αβγδ) nAChR expressed in Xenopus oocytes with IC50 values of ∼ 1 μM. dFBr also inhibited the equilibrium binding of ion channel blockers to Torpedo nAChRs with higher affinity in the nAChR desensitized state ([(3)H]phencyclidine; IC50 = 4 μM) than in the resting state ([(3)H]tetracaine; IC50 = 60 μM), whereas it bound with only very low affinity to the ACh binding sites ([(3)H]ACh, IC50 = 1 mM). Upon irradiation at 312 nm, [(3)H]dFBr photoincorporated into amino acids within the Torpedo nAChR ion channel with the efficiency of photoincorporation enhanced in the presence of agonist and the agonist-enhanced photolabeling inhibitable by phencyclidine. In the presence of agonist, [(3)H]dFBr also photolabeled amino acids in the nAChR extracellular domain within binding pockets identified previously for the nonselective nAChR PAMs galantamine and physostigmine at the canonical α-γ interface containing the transmitter binding sites and at the noncanonical δ-β subunit interface. These results establish that dFBr inhibits muscle-type nAChR by binding in the ion channel and that [(3)H]dFBr is a photoaffinity probe with broad amino acid side chain reactivity.

Indexed as

AnimalsBinding SitesHumansHydrocarbons, BrominatedIndole AlkaloidsModels, MolecularMusclesPhotoaffinity LabelsReceptors, NicotinicTorpedoXenopus laevisdesformylflustrabromineHydrocarbons, BrominatedIndole AlkaloidsPhotoaffinity LabelsReceptors, Nicotinic

Identifiers

PMID25870334
PMCPMC4468644
OpenAlexW2325786992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.